Day: September 18, 2020

TORONTO, Sept. 18, 2020 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company“) announces pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and applicable Canadian securities legislation that on September 17, 2020, the Company completed a disposition of 6,000,000 common shares and $400,000 worth of convertible debentures of Inner Spirit Holdings Ltd. (“Inner Spirit”) for gross proceeds of $845,400, which reduces Auxly’s security holding percentage in Inner Spirit from 12.9% to 9.8%. The disposition was completed through the Canadian Securities Exchange where Inner Spirit’s common shares and convertible debentures are listed for trading. Since Auxly’s security holding percentage...

—Advancing VERU-111 to a Pivotal Phase 3 Clinical Program—MIAMI, Sept. 18, 2020 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that positive clinical results from its Phase 1b study of VERU-111 were orally presented at the European Society for Medical Oncology (ESMO) Congress 2020.The results of the Phase 1b study evaluating VERU-111, a novel oral microtubule targeting agent that selectively inhibits alpha and beta tubulin, in 39 men with metastatic castration resistant prostate cancer that have also failed at least one androgen receptor targeting agent (enzalutamide or abiraterone) and a large and growing unmet medical need in advanced prostate cancer, have been presented as an oral presentation...

FLORIANÓPOLIS, Brazil, Sept. 18, 2020 (GLOBE NEWSWIRE) — Vitru Limited (“Vitru”), a Brazilian distance learning education group company, today announced the pricing of its initial public offering of 6,000,000 of its newly-issued common shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a public offering price of $16.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on September 18, 2020, under the symbol “VTRU” and the offering is expected to close on September 22, 2020, subject to customary closing conditions.In connection with the offering, Vitru has granted the underwriters a 30-day option to purchase up to an additional 900,000 common shares at the initial public offering price, less underwriting discounts and commissions.Goldman...

CAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Michael Kamarck, Ph.D., to its Board of Directors, effective immediately.“We are excited to welcome Dr. Kamarck to the board of directors,” said Robert L. Kirkman, M.D., Chair of Trillium Therapeutics.  “His long experience and expertise with the development and manufacturing of biologic products will be of particular value as Trillium is preparing to scale up its clinical development activities, with multiple phase 2 programs expected to start next year.”Dr. Kamarck has significant expertise in biologics manufacturing and a breadth of management...

PALM BAY, Fla., Sept. 18, 2020 (GLOBE NEWSWIRE) — LGI Homes, Inc. (Nasdaq:LGIH) today announced the introduction of brand-new, single-family homes in the city of Palm Bay, Florida.  Located off I-95 in southeast Orlando, LGI homeowners living in Palm Bay will have convenient access to nearby attractions for the entire family. The white-sand beaches of Melbourne Beach provide Palm Bay residents with gorgeous sunset views all year long. Business and leisure travelers can appreciate the quick access to the Orlando Melbourne International Airport, where direct flights for domestic and international travel are constantly expanding. In addition, retail therapy can be enjoyed nearby at the Vero Beach Outlets, where tremendous value is offered at over 40 designer and name brand retail stores.Palm Bay by LGI Homes is offering an array of...

– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate– Company to host virtual KOL event to review data today at 8:00am ETREHOVOT, Israel and WILMINGTON, Del., Sept. 18, 2020 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (Ayala or the Company), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced positive interim results from the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations in a mini oral presentation at the European Society for Medical Oncology...

NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) — Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System (Mount Sinai) in New York City. KidneyIntelX risk assessment of progressive decline in kidney function or kidney failure, including education support for treating clinicians, is now commercially available for patients with early stage diabetic kidney disease (DKD). In addition to patient testing and risk assessment, a central component of this launch milestone is the physician education and support program developed in close collaboration...

CALGARY, Alberta, Sept. 18, 2020 (GLOBE NEWSWIRE) — The Board of Directors of Computer Modelling Group Ltd. (“CMG” or the “Company”) is pleased to announce the appointment of Kelly Tomyn as Interim Vice President, Finance and Chief Financial Officer of the Company effective September 21, 2020. Ms. Tomyn is assuming the role while CMG’s current Vice President, Finance and Chief Financial Officer, Sandra Balic, takes a parental leave of absence for a period of approximately 12 months.Ms. Tomyn is an experienced finance leader with over 25 years of experience in the oil and gas industry. She brings 18 years of diverse business experience serving in Chief Financial Officer roles with a focus on public companies and has a wide breadth of experience in all aspects of financial operations and business strategy. Ms. Tomyn is...

Successfully completed IPO in August 2020 raising $76.6 million in gross proceedsOn track to initiate planned new clinical trials in melanoma and head and neck cancerCAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced second quarter 2020 financial results and provided an update on recent progress.“This is an exciting time for our company as we rapidly develop CMP-001 across multiple tumor types in combination with checkpoint inhibitors,” said Barry Labinger, Chief Executive Officer. “Our recent public offering positions us well to execute on our clinical and strategic plans, including advancement of CMP-001 towards...

ATLANTA, Sept. 18, 2020 (GLOBE NEWSWIRE) — Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks’ digital channels, today announced the pricing of $200 million principal amount of 1.00% convertible senior notes due 2025 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cardlytics also granted the initial purchasers of the notes an option to purchase up to an additional $30 million principal amount of notes. The sale of the notes is expected to close on September 22, 2020, subject to customary closing conditions.The notes will be general unsecured obligations of Cardlytics and will accrue interest payable semiannually in arrears on March 15 and September 15 of each year,...